Annual report pursuant to Section 13 and 15(d)

Collaborative Arrangements - Takeda (Details)

v3.20.4
Collaborative Arrangements - Takeda (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Mar. 31, 2020
Dec. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Contract liabilities, deferred revenue $ 4,791   $ 2,044
Takeda      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Contract liabilities, deferred revenue 1,500    
Liability, revenue recognized $ 13,200    
Takeda | Up-front Payment      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Contract liabilities, deferred revenue   $ 8,500  
Takeda | Research and Development Reimbursement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Contingent receivable   15,400  
Takeda | Milestone Payment Per Target Gene      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Contingent receivable   $ 100,000